Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.65 |
| ▸ | NPY1R | P25929 | 6/20 | 0.65 |
| ▸ | NPY2R | P49146 | 4/20 | 0.65 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.65 |
| ▸ | KISS1R | Q969F8 | 11/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434605 | 0.95 | NPY4R (0.71) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL29434583 | 0.92 | NPY4R (0.67) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL31174227 | 0.92 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL29767744 | 0.92 | NPY4R (0.72) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL29767742 | 0.92 | NPY4R (0.72) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL31666017 | 0.91 | NPY4R (0.71) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29901561 | 0.91 | NPY4R (0.71) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL29434645 | 0.91 | NPY4R (0.73) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL30827582 | 0.91 | NPY4R (0.70) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL29442105 | 0.91 | TFPI (0.61) | NPY4RNPY1RNPY2RNPY5RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261237-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | NORTHWESTERN UNIVERSITY (US) | 2022-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261237-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | VEGFA, LITAF, FIBP | NPY4R 2058/4885NPY1R 1616/4885NPY2R 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.